Legal News
Whistleblower claims Siemens’ China division fired him for exposing bribery scheme
Lawsuits accuse Fresenius of concealing on GranuFlo, NaturaLyte risks
A spate of lawsuits accuse Fresenius Medical (NYSE:FMS) of deliberately concealing potentially fatal problems with a pair of since-recalled products used during dialysis.
Abbott still on the hook in stent off-label marketing lawsuit
MIT and Children’s Medical sue Shire over DermaGraft diabetic foot ulcer treatment
San Diego Chargers team doctor sues Smith & Nephew over botched hip implant
A doctor who blames a botched hip implantation on Smith & Nephew (FTSE:SN, NYSE:SNN) is suing the British medical device company to recoup his $2.2 million malpractice loss.
Appeals court overturns Arthrex win over Smith & Nephew
The latest turn in a nearly decade-long legal battle between Smith & Nephew (FTSE:SN, NYSE:SNN) and Arthrex over surgical anchor patents swung Smith & Nephew’s way yesterday, when the U.S. Court of Appeals for the Federal Circuit overturned a lower court’s ruling and sent the case back for reconsideration.
MassDevice.com +3 | The top 3 med-tech stories for Jan. 15, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Juror selection begins for Johnson & Johnson transvaginal mesh lawsuits | MassDevice.com On Call
MASSDEVICE ON CALL — A bellwether trial against Johnson & Johnson (NYSE:JNJ) began this month with lawyers beginning to select jurors to hear a lawsuit accusing the healthcare giant of liability patient injuries allegedly caused by the company’s transvaginal mesh implants.
Supreme Court denies W.L. Gore in stent graft patent spat with C.R. Bard
The U.S. Supreme Court dashed the last hopes of W.L. Gore & Assoc. in its long-running patent war with C.R. Bard (NYSE:BCR) over vascular graft technology.